NEXLIZET® & NEXLETOL® HCP Information - Official Site
The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0.5% greater than placebo …
What Is NEXLETOL®? - Learn More About This Nonstatin Option
The most common side effects of NEXLETOL in people with heart problems include: Kidney problems, anemia, increased liver enzymes, muscle spasms, and gallstones NEXLETOL can cause serious …
Nexletol: Uses, Dosage, Side Effects, Warnings - Drugs.com
Aug 5, 2024 · Nexletol (bempedoic acid) is an oral tablet for high cholesterol that may be used to lower the risk of heart attack and heart procedures (for example stent placement or bypass surgery), in …
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® …
ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new …
U.S. FDA Approves Broad New Labels for NEXLETOL® and
Mar 22, 2024 · The U.S. approvals of NEXLIZET and NEXLETOL for cardiovascular risk reduction and LDL-C lowering were based on data generated from the CLEAR Outcomes trial, which was …
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant ...
Mar 4, 2023 · The patients were required to provide written confirmation that they were statin intolerant and aware of the benefits of statins in reducing the risk of cardiovascular events, including death, as ...
Nexletol Overview: Side Effects, Uses, Dosage, and More
Apr 30, 2025 · Nexletol (bempedoic acid) is a prescription tablet that treats high cholesterol and reduces heart-related risks in certain adults. Learn about dosage, side effects, and more.
Esperion Partners with Neopharm to Commercialize NEXLETOL® …
Dec 12, 2024 · The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0.5% greater than …
FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart ... - AJMC
Mar 22, 2024 · U.S. FDA approves broad new labels for Nexletol and Nexlizet to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of …
U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to …
April 1, 2024 — Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL (bempedoic acid) Tablets and NEXLIZET …